Consistently, the knockout of SOCS1 in CD8+ T cells, a potent inhibitor of IL-2 family cytokine signaling (23), obviated the need for CD4+ help to sustain long-term BsAb-mediated target tumor cell killing by CD8+ T cells, whereas its knockout in CD4+ cells failed to impact CD8+ responses in this assay context. The gene discussed is CD8A; the disease is neoplasm.